$TTPH breakout candle $6.95 Above upper bollie
Post# of 106844
(Total Views: 70)
Posted On: 03/13/2017 7:45:23 AM
$TTPH breakout candle $6.95
Above upper bollie
Nasdaq GM
Website
Last ten trades
100% x 100% Strong Buy
10-Q 11/3/16
Low float
Shares Outstanding 36.94M
Float 36.67M
% Held by Insiders 32.15%
% Held by Institutions 67.40%
Shares Short 3 1.74M
Short Ratio 4.52
Short % of Float 4.82%
Shares Short (prior month) 1.69M
Stock technical analysis
news
and filings
Our proprietary chemistry technology, licensed from Harvard on an exclusive worldwide basis and enhanced at Tetraphase, represents a significant innovation in the creation of tetracycline drugs.
The tetracycline class of antibiotics has been used successfully for more than 50 years. Using conventional methods, tetracyclines are produced semi-synthetically, first in bacteria and then modified in a limited number of ways by available chemistry. These traditional approaches have only been able to produce tetracycline antibiotics with limited chemical diversity, making it difficult to create tetracycline antibiotics that address a wide variety of multidrug-resistant bacteria.
By contrast, our proprietary technology makes it possible to create novel tetracycline antibiotics using a practical, fully-synthetic process. This fully-synthetic process allows us to chemically modify many positions on the tetracycline core structure, including most of the positions that could not practically be modified by any previous method. Using our proprietary chemistry technology, we can create a wider variety of tetracycline-based compounds than was previously possible, enabling us to pursue novel tetracycline derivatives for the treatment of multidrug-resistant bacteria that are resistant to existing tetracyclines and other classes of antibiotics.
The diagram below illustrates the tetracycline core structure. The positions marked with green dots have been modified to date using semi-synthetic approaches to create tetracycline analogs. These positions can also be modified with our fully-synthetic process, but with much greater opportunity for substitution. In addition, the positions marked with red dots in the diagram cannot be practically modified using semi-synthesis—only our fully-synthetic technology allows the preparation of structural variations at these positions.
Above upper bollie
Nasdaq GM
Website
Last ten trades
100% x 100% Strong Buy
10-Q 11/3/16
Low float
Shares Outstanding 36.94M
Float 36.67M
% Held by Insiders 32.15%
% Held by Institutions 67.40%
Shares Short 3 1.74M
Short Ratio 4.52
Short % of Float 4.82%
Shares Short (prior month) 1.69M
Stock technical analysis
news
and filings
Our proprietary chemistry technology, licensed from Harvard on an exclusive worldwide basis and enhanced at Tetraphase, represents a significant innovation in the creation of tetracycline drugs.
The tetracycline class of antibiotics has been used successfully for more than 50 years. Using conventional methods, tetracyclines are produced semi-synthetically, first in bacteria and then modified in a limited number of ways by available chemistry. These traditional approaches have only been able to produce tetracycline antibiotics with limited chemical diversity, making it difficult to create tetracycline antibiotics that address a wide variety of multidrug-resistant bacteria.
By contrast, our proprietary technology makes it possible to create novel tetracycline antibiotics using a practical, fully-synthetic process. This fully-synthetic process allows us to chemically modify many positions on the tetracycline core structure, including most of the positions that could not practically be modified by any previous method. Using our proprietary chemistry technology, we can create a wider variety of tetracycline-based compounds than was previously possible, enabling us to pursue novel tetracycline derivatives for the treatment of multidrug-resistant bacteria that are resistant to existing tetracyclines and other classes of antibiotics.
The diagram below illustrates the tetracycline core structure. The positions marked with green dots have been modified to date using semi-synthetic approaches to create tetracycline analogs. These positions can also be modified with our fully-synthetic process, but with much greater opportunity for substitution. In addition, the positions marked with red dots in the diagram cannot be practically modified using semi-synthesis—only our fully-synthetic technology allows the preparation of structural variations at these positions.
(0)
(0)